Rare diseases Cardiology Conference update

Advancing ATTR-CM care: From disease understanding to evolving treatment strategies

Highlights from ESC 2026 symposia on ATTR-CM

Prof. Teresa Trenkwalder

Publication Date

Aug 2026

Downloadable resources

I agree that this programme:

Was valuable to me

1/3

Has improved my knowledge of this topic:

2/3

Is likely to change my clinical practice:

3/3

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a treatable disease, yet patients often experience delayed diagnosis and access to the most appropriate treatment.

Prof. Teresa Trenkwalder joined us live at ESC 2026 to record a short video sharing her highlights from three Alnylam symposia exploring the importance of earlier recognition of ATTR-CM and the impact of emerging therapies.

Watch Prof. Trenkwalder's video and view a selection of the slides from the symposia presentations to examine the latest clinical evidence that may influence future treatment strategies for patients with ATTR-CM.

Clinical takeaways

ATTR-CM remains frequently misdiagnosed despite improved disease recognition and increased use of background therapy, highlighting a persistent unmet need in contemporary patients
RNA interference (RNAi) therapeutics address the root cause of ATTR-CM by targeting transthyretin at its source
Vutrisiran treatment demonstrated consistent clinical benefits in patients with ATTR-CM and is considered a first-line treatment option in ATTR-CM

Recognise key developments in the understanding and management of ATTR-CM, including ongoing challenges in patient care
Understand the scientific rationale for RNAi-based therapies and their role within the evolving ATTR-CM treatment paradigm
Assess how new clinical data and real-world experience may influence future treatment strategies and outcomes for patients with ATTR-CM

Prof. Teresa Trenkwalder is a senior attending physician in the Department of Cardiology at TUM University Hospital, German Heart Center Munich. Clinically, she specialises in non-invasive cardiology, with a focus on echocardiographic imaging as well as the diagnosis and treatment of cardiomyopathies and heart failure. Her research focuses on the genetics and treatment of structural heart disease, particularly cardiomyopathies and amyloidosis.

Prof. Teresa Trenkwalder has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Speaker and travel grants: Pfizer, Alnylam, Zoll, Novartis, AstraZeneca, Alexion, Bayer, Bristol Myers Squibb, Zoll, Boehringer Ingelheim, GE HealthCare and Edwards.

Download Slides - PDF